Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alogliptin
Drug ID BADD_D00079
Description Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Indications and Usage Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Marketing Status Prescription
ATC Code A10BH04
DrugBank ID DB06203
KEGG ID D06553
MeSH ID C520853
PubChem ID 11450633
TTD Drug ID D0NJ5H
NDC Product Code 65392-2813; 64764-625; 11532-7002; 71610-300; 66332-7003; 45802-150; 64764-250; 64764-125; 45802-103; 45802-087; 11532-7003; 50090-5574; 11532-7001; 66332-7002; 66332-7001
Synonyms alogliptin | 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile | nesina | SYR 322 | SYR322 | SYR-322
Chemical Information
Molecular Formula C18H21N5O2
CAS Registry Number 850649-61-5
SMILES CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Acute hepatic failure09.01.03.001--Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000200%Not Available
Alanine aminotransferase increased13.03.01.0030.000300%
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.0070.000200%Not Available
Angina pectoris02.02.02.002; 24.04.04.0020.000400%
Angioedema10.01.05.009; 23.04.01.001--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.0060.000400%
Back pain15.03.04.0050.000300%
Bile duct cancer09.04.02.001; 16.07.01.0010.000157%Not Available
Blister12.01.06.002; 23.03.01.0010.000052%Not Available
Blood creatine phosphokinase increased13.04.01.0010.000200%
Blood creatinine increased13.13.01.0040.000200%
Blood glucose increased13.02.02.0020.000300%Not Available
Blood potassium increased13.11.01.0110.000300%Not Available
Blood uric acid increased13.02.04.0010.000200%Not Available
Cardiac failure02.05.01.0010.000131%
Cataract06.06.01.0010.000200%
Cerebral haemorrhage17.08.01.003; 24.07.04.0010.000052%Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.000501%Not Available
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Cholecystitis09.03.01.0010.000200%
Colitis ischaemic07.08.01.004; 24.04.08.0120.000200%Not Available
Colon cancer07.21.01.001; 16.13.01.0010.000209%Not Available
Constipation07.02.02.0010.000300%
Death08.04.01.001--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene